Harbin Medisan Pharmaceutical Co Ltd (002900) - Total Assets
Based on the latest financial reports, Harbin Medisan Pharmaceutical Co Ltd (002900) holds total assets worth CN¥3.61 Billion CNY (≈ $528.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Harbin Medisan Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Harbin Medisan Pharmaceutical Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Harbin Medisan Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Harbin Medisan Pharmaceutical Co Ltd (002900) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Harbin Medisan Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Harbin Medisan Pharmaceutical Co Ltd's total assets of CN¥3.61 Billion consist of 38.7% current assets and 61.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.9% |
| Accounts Receivable | CN¥234.55 Million | 6.2% |
| Inventory | CN¥307.67 Million | 8.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥151.51 Million | 4.0% |
| Goodwill | CN¥1.34 Million | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Harbin Medisan Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Harbin Medisan Pharmaceutical Co Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harbin Medisan Pharmaceutical Co Ltd's current assets represent 38.7% of total assets in 2024, a decrease from 41.4% in 2012.
- Cash Position: Cash and equivalents constituted 20.9% of total assets in 2024, up from 11.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 9.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 8.1% of total assets.
Harbin Medisan Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Harbin Medisan Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Harbin Medisan Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.97 | 1.25 | 2.45 |
| Quick Ratio | 0.76 | 1.02 | 2.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-32.18 Million | CN¥269.44 Million | CN¥851.32 Million |
Harbin Medisan Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Harbin Medisan Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.00 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 10.4% |
| Total Assets | CN¥3.80 Billion |
| Market Capitalization | $456.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Harbin Medisan Pharmaceutical Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Harbin Medisan Pharmaceutical Co Ltd's assets grew by 10.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual total assets of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.80 Billion ≈ $556.13 Million |
+10.38% |
| 2023-12-31 | CN¥3.44 Billion ≈ $503.82 Million |
+5.07% |
| 2022-12-31 | CN¥3.28 Billion ≈ $479.50 Million |
+6.89% |
| 2021-12-31 | CN¥3.07 Billion ≈ $448.58 Million |
+23.47% |
| 2020-12-31 | CN¥2.48 Billion ≈ $363.31 Million |
-7.09% |
| 2019-12-31 | CN¥2.67 Billion ≈ $391.02 Million |
+6.31% |
| 2018-12-31 | CN¥2.51 Billion ≈ $367.81 Million |
+15.10% |
| 2017-12-31 | CN¥2.18 Billion ≈ $319.55 Million |
+87.26% |
| 2016-12-31 | CN¥1.17 Billion ≈ $170.65 Million |
+10.76% |
| 2015-12-31 | CN¥1.05 Billion ≈ $154.08 Million |
+8.50% |
| 2014-12-31 | CN¥970.46 Million ≈ $142.01 Million |
+13.14% |
| 2013-12-31 | CN¥857.75 Million ≈ $125.52 Million |
+19.30% |
| 2012-12-31 | CN¥719.01 Million ≈ $105.21 Million |
-- |
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more